Washington, D.C. 20549


                                    FORM 6-K


                            REPORT OF FOREIGN ISSUER

                       Pursuant to Rule 13a-16 or 15d-16
                     of the Securities Exchange Act of 1934

                                  MARCH 10 2005


                                NOVO NORDISK A/S
             (Exact name of Registrant as specified in its charter)

                                    NOVO ALLE
                               DK-2880, BAGSVAERD
                    (Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

                       Form 20-F [X]     Form 40-F [ ]

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                             Yes [ ]     No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________



At the Annual General Meeting of Novo Nordisk A/S today, the shareholders made
the following resolutions:

*    Adoption of the  audited  Annual  Report  2004,  including  approval of the
     remuneration of the Board of Directors.

*    Resolution to distribute the profit  according to the adopted Annual Report
     2004.  The dividend  will be DKK 4.80 per share of DKK 2, an increase of 9%
     compared with 2003.

*    Board members  elected by the Annual General  Meeting:  Re-election of Mads
     Ovlisen, Sten Scheibye, Kurt Briner, Niels Jacobsen, Kurt Anker Nielsen and
     Jorgen Wedel and election of Goran A Ando and Henrik Gurtler.

*    Re-election of the auditor, PricewaterhouseCoopers.

*    Authorisation  to the Board of  Directors,  until the next  Annual  General
     Meeting,  to allow Novo  Nordisk  A/S to acquire own shares of up to 10% of
     the share  capital and at the price  quoted on the date of purchase  with a
     deviation of up to 10%, cf Article 48 of the Danish Companies Act.

The Board of Directors

Accordingly the Board of Directors of Novo Nordisk A/S comprises:

*    Mads Ovlisen
*    Sten Scheibye
*    Goran A Ando
*    Kurt Briner
*    Henrik Gurtler
*    Johnny Henriksen (employee representative)
*    Niels Jacobsen
*    Anne Marie Kverneland (employee representative)
*    Kurt Anker Nielsen
*    Stig Strobaek (employee representative)
*    Jorgen Wedel

For information on the board members, please refer to novonordisk.com.

At a board meeting immediately after the Annual General Meeting, the Board of
Directors constituted itself with Mads Ovlisen as chairman and Sten Scheibye as
vice chairman.

The Board of Directors elected Kurt Anker Nielsen, Niels Jacobsen and Jorgen
Wedel as members of the Audit Committee with Kurt Anker Nielsen as chairman.
Kurt Anker Nielsen and Niels Jacobsen were designated by the Board of Directors
as Audit Committee Financial Experts.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 20,250 full-time
employees in 78 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For
more information, visit novonordisk.com.

For further information please contact:

Media:                              Investors:
Outside North America:              Outside North America:
Mike Rulis                          Mogens Thorsager Jensen
Tel (direct): (+45) 4442 3573       Tel (direct): (+45) 4442 7945

                                    Palle Holm Olesen
                                    Tel (direct): (+45) 4442 6175

In North America:                   In North America:
Susan T Jackson                     Christian Kanstrup
Tel (direct): (+1) 609 919 7776     Tel (direct): (+1) 609 919 7937

Stock Exchange Announcement No 13 /2005


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf of the
undersigned, thereunto duly authorized.

Date: MARCH 10 2005                           NOVO NORDISK A/S
                                            Lars Rebien Sorensen,
                                     President and Chief Executive Officer